References
- Lambotte O , DeivaK, TardieuM. HIV-1 persistence, viral reservoir, and the central nervous system in the HAART era. Brain Pathol.13, 95–103 (2003).
- Saksena N , WangB, ZhouL, SoedjonoM, HoYS, ConceicaoV. HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites. HIV AIDS Res. Palliat. Care2, 103–122 (2010).
- Kandanearatchi A , WilliamsB, EverallIP. Assessing the efficacy of highly active antiretroviral therapy in the brain. Brain Pathol.13, 104–110 (2003).
- Letendre S , Marquie-BeckJ, CapparelliEet al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch. Neurol. 65, 65–70 (2008).
- Tozzi V , BalestraP, SalvatoriMFet al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J. Acquir. Immune Defic. Syndr. 52, 56–63 (2009).
- Richman DD , MargolisDM, DelaneyM, GreeneWC, HazudaD, PomerantzRJ. The challenge of finding a cure for HIV infection. Science323, 1304–1307 (2009).
- Trono D , Van Lint C, Rouzioux C et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science329, 174–180 (2010).
- Thomas SA . Anti-HIV drug distribution to the central nervous system. Curr. Pharm. Des.10, 1313–1324 (2004).
- Gimenez F , FernandezC, MabondzoA. Transport of HIV protease inhibitors through the blood–brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins. J. Acquir. Immune Defic. Syndr.36, 649–658 (2004).
- Varatharajan L , ThomasSA. The transport of anti-HIV drugs across blood–CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res.82, A99–A109 (2009).
- Loscher W , PotschkaH. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci.6, 591–602 (2005).
- Gottesman MM , HrycynaCA, SchoenleinPV, GermannUA, PastanI. Genetic analysis of the multidrug transporter. Annu. Rev. Genet.29, 607–649 (1995).
- Raviv Y , PollardHB, BruggemannEP, PastanI, GottesmanMM. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J. Biol. Chem.265, 3975–3980 (1990).
- Aller SG , YuJ, WardAet al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323, 1718–1722 (2009).
- Cameron DW , JapourAJ, XuYet al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 13, 213–224 (1999).
- Foisy MM , YakiwchukEM, HughesCA. Induction effects of ritonavir: implications for drug interactions. Ann. Pharmacother.42, 1048–1059 (2008).
- Sauna ZE , AndrusMB, TurnerTM, AmbudkarSV. Biochemical basis of polyvalency as a strategy for enhancing the efficacy of P-glycoprotein (ABCB1) modulators: stipiamide homodimers separated with defined-length spacers reverse drug efflux with greater efficacy. Biochemistry43, 2262–2271 (2004).
- Pires MM , HrycynaCA, ChmielewskiJ. Bivalent probes of the human multidrug transporter P-glycoprotein. Biochemistry45, 11695–11702 (2006).
- Pires MM , EmmertD, HrycynaCA, ChmielewskJ. Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers. Mol. Pharmacol.75, 92–100 (2009).
- Namanja HA , EmmertD, DavisDAet al. Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood–brain barrier with prodrug abacavir dimers. J. Am. Chem. Soc. 134, 2976–2980 (2012).